Sema4 (NASDAQ:SMFR) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Sema4 (NASDAQ:SMFRGet Rating) from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. They currently have $2.00 price target on the stock.

According to Zacks, “Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn. “

A number of other equities research analysts have also weighed in on SMFR. Compass Point decreased their price objective on shares of Sema4 to $5.00 and set a na rating for the company in a report on Monday, May 16th. Cowen decreased their price objective on shares of Sema4 from $13.00 to $5.00 in a report on Monday, May 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Sema4 currently has an average rating of Buy and an average target price of $7.50.

Shares of NASDAQ:SMFR opened at $2.16 on Wednesday. Sema4 has a 52 week low of $1.49 and a 52 week high of $15.21. The company has a current ratio of 4.08, a quick ratio of 3.72 and a debt-to-equity ratio of 0.03. The company’s fifty day moving average is $2.40 and its 200 day moving average is $3.69.

Sema4 (NASDAQ:SMFRGet Rating) last released its quarterly earnings results on Monday, March 14th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05. The firm had revenue of $57.80 million for the quarter, compared to analysts’ expectations of $50.90 million. As a group, sell-side analysts forecast that Sema4 will post -0.76 EPS for the current fiscal year.

In other Sema4 news, major shareholder Tactical Opportunit Blackstone purchased 2,500,000 shares of Sema4 stock in a transaction dated Friday, April 29th. The stock was acquired at an average price of $4.00 per share, for a total transaction of $10,000,000.00. Following the acquisition, the insider now owns 26,839,187 shares in the company, valued at approximately $107,356,748. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Keith A. Meister purchased 11,437,500 shares of Sema4 stock in a transaction dated Friday, April 29th. The stock was acquired at an average price of $4.00 per share, with a total value of $45,750,000.00. Following the acquisition, the director now owns 26,931,250 shares in the company, valued at approximately $107,725,000. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 14,037,500 shares of company stock valued at $55,942,000 and sold 33,099 shares valued at $79,156.

Several institutional investors have recently modified their holdings of SMFR. BlackRock Inc. purchased a new position in shares of Sema4 in the 3rd quarter worth approximately $12,674,000. Citigroup Inc. purchased a new position in shares of Sema4 in the 3rd quarter worth approximately $79,000. Goldman Sachs Group Inc. purchased a new position in shares of Sema4 in the 3rd quarter worth approximately $115,000. Magnetar Financial LLC purchased a new position in shares of Sema4 in the 3rd quarter worth approximately $247,000. Finally, Geode Capital Management LLC purchased a new position in shares of Sema4 in the 3rd quarter worth approximately $9,084,000.

About Sema4 (Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

Further Reading

Get a free copy of the Zacks research report on Sema4 (SMFR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.